NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Xtant Medical Holdings, Inc. XTNT
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$133.9M
▲ 14.2% vs FY2024
EPS · FY25
$0.03
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
10.6%
Net margin · FY25
3.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 133.9M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
4 cents of every revenue dollar became profit this year.
Per share
USD 0.03
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
10.6%
Return on equity, FY2025
ROE
Operating margin5.4%
Net margin3.7%
Return on assets5.3%
Each USD of equity produced 11 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+20.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+32.2%
+20.2%
+8.5%
+15.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.14B
Shares outstanding, FY2025
Change, 5 years+80.5%
Change, 10 years—
The share count grew 81% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 94.1M
total assets, end of FY2025
Total assetsUSD 94.1M
EquityUSD 51.0M
CashUSD 17.1M
Gross debtUSD 14.5M
Net debtUSD -2.5M
Current ratio2.65×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
·
0.0
0.0
·
0.0
0.0
−0.0
0.0
0.0
0.0
·
·
Net income $B
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.03
−0.12
0.01
−0.09
−0.06
−0.25
−0.63
−5.97
−34.76
−18.46
−0.24
−1.76
−2.80
−0.18
−0.08
−0.61
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
10.6
−34.9
1.5
−26.1
−21.4
·
·
·
·
−2162.9
−394.8
·
−6505.8
−158.5
−123.2
·
Shares out B
0.14
0.14
0.13
0.11
0.09
0.08
0.01
0.01
0.00
0.00
0.01
0.01
0.01
0.04
0.04
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 64
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed